Preclinical metabolism and disposition of tp0473292, a novel oral prodrug of the potent metabotropic glutamate 2/3 receptor antagonist tp0178894 for the treatment of depression

HIGHLIGHTS

• who: Title Page et al. from the Research Headquarters, Taisho Pharmaceutical Co, Ltd, Saitama, Japan have published the Article: Preclinical metabolism and disposition of TP0473292, a novel oral prodrug of the potent metabotropic glutamate 2/3 receptor antagonist TP0178894 for the treatment of depression, in the Journal: (JOURNAL)
• what: This study reports the preclinical pharmacokinetics of a hydrophilic metabotropic glutamate 2/3 receptor antagonist despite being activated predominantly in the intestine. In this research, preclinical pharmacokinetic studies were conducted to evaluate whether pharmacokinetic drug-drug interaction (DDI) potential of TP0473292 and its metabolites via cytochrome . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.